Supervisory Board

Affimed's Supervisory Board is made up of
highly experienced experts from the
pharmaceutical and biotechnology industries.

 
 
     
 
  Supervisory Board  
   
 
 
 
Dr. Thomas Hecht, Chairman
 
Dr. Hecht has been the Chairman of Affimed’s Supervisory Board since 2007. He is Head of Hecht Healthcare Consulting in Küssnacht, Switzerland, a biopharmaceutical consulting company founded in 2002. Dr. Hecht also serves as Chairman of the Board of Directors of Cell Medica Ltd., Delenex AG, Vaximm AG and as a Director of Humabs BioMed AG. Until the beginning of March 2015, he served as Chairman of the Supervisory Council of SuppreMol GmbH. Dr. Hecht was previously Vice President Marketing at Amgen Europe. A seasoned manager and industry professional, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, he was certified in internal medicine and served as Co-Head of the Program for Bone Marrow Transplantation at the University of Freiburg, Germany.
 

Ferdinand Verdonck, J.D. Chair of Audit Committee

 
Mr. Verdonck has been a member of Affimed’s Supervisory Board since July 2014. He is a Director and member of the Audit Committee of Virtus Funds and member of the Board of Laco Information Services. In recent years he was Chairman of the Supervisory Board of uniQure N.V., a member of the Board of Group SNEF and of J.P. Morgan European Investment Trust and a member of the Board of Directors and Chairman of the Audit Committee of two biotechnology companies in Belgium, Movetis and Galapagos. He has previously served as Chairman of Banco Urquijo and of Nasdaq Europe and as a Director of Dictaphone Corporation. From 1992 to 2003, he was the Managing Director of Almanij NV, a financial services company which has since merged with KBC, and his responsibilities included company strategy, financial control, supervision of executive management and corporate governance, including board participation in publicly-traded and privately-held companies in many countries. Mr. Verdonck holds a law degree from KU Leuven and degrees in economics from KU Leuven and the University of Chicago.
 
Berndt Modig, M.B.A.
 
Mr. Modig has been a member of Affimed’s Supervisory Board since 2014. He has served as Chief Financial Officer of Prosensa Holding N.V. from March 2010 through January 2015 when Prosensa was acquired by BioMarin Pharmaceutical Inc. Mr. Modig also serves as member of the Board of Directors and Chairman of the Audit Committee of Auris Medical Holding AG and Axovant Sciences Ltd. Mr. Modig has more than 25 years of international experience in finance and operations, private equity and mergers and acquisitions. Before joining Prosensa, Mr. Modig was Chief Financial Officer at Jerini AG from October 2003 to November 2008, where he directed private financing rounds, its initial public offering in 2005 and its acquisition by Shire plc in 2008. Prior to Jerini, Mr. Modig served as Chief Financial Officer at Surplex AG from 2001 to 2003 and as Finance Director Europe of U.S.-based Hayward Industrial Products Inc. from 1999 to 2001. In previous positions, Mr. Modig was a partner in the Brussels-based private equity firm Agra Industria from 1994 to 1999 and a senior manager in the financial services industry group of Price Waterhouse LLP in New York from 1991 to 1994. Mr. Modig served as a Director of Mobile Loyalty plc from 2012 to 2013. Mr. Modig has a bachelor’s degree in business administration, economics and German from the University of Lund, Sweden and an M.B.A. degree from INSEAD, Fontainebleau, France and is a Certified Public Accountant.
 
 
Dr. Richard Stead
 
Dr. Stead has been a member of Affimed’s Supervisory Board since 2007. He has more than 25 years of experience in the biotechnology and pharmaceutical industries, designing and directing clinical trials, regulatory strategy and licensing activities. He is currently Founder and Principal of BioPharma Consulting Services, where he is involved in the development of a number of oncology products including different strategies for cancer immunotherapy. Previously, he was Vice President, Clinical Research of Immunex Corporation, responsible for oncology and neurology product development. Dr. Stead has served in various positions in clinical development and played a key role in the FDA approval and commercialization of Amgen’s first two products, Epogen and Neupogen. Dr. Stead graduated from the University of Wisconsin and earned an M.D. from Stanford University. He completed his internship and residency as well as a fellowship in hematology at Harvard Medical School and the Brigham and Women’s Hospital followed by post-doctoral research in the Laboratory of Molecular Biology at the National Cancer institute. He also serves on the boards of Ascend Biopharmaceuticals Ltd. and the Seattle Repertory Theatre.
 
Dr. Ulrich Grau
 
Dr. Grau served as an advisor to Affimed’s board from May 2013 until June 2015 and became a board member in July 2015. He has over 30 years of experience in the biotechnology and pharmaceutical industries including general management, business development, corporate strategy and the development of new products and technologies. Dr. Grau was Chief Operating Officer at Micromet from 2011 to 2012. Between 2006 and 2010, Dr. Grau was a founder, President and CEO of Lux Biosciences, Inc., a clinical stage ophthalmic company. Previously, Dr. Grau served as President of Research and Development at BASF Pharma/Knoll where he directed a global R&D organization whose development pipeline included Humira. The majority of his career was at Aventis Pharma, where he last held the position of Senior VP of Global Late Stage Development. Lantus® is based on his inventions made during his early years as a scientist with Hoechst AG. Dr. Grau received his Ph.D. in chemistry and biochemistry from the University of Stuttgart and spent three years as a post-doctoral fellow at Purdue University in the field of protein crystallography.
 
Dr. Bernhard Ehmer
 
Dr. Ehmer has been a member of Affimed’s Supervisory Board since 2016. He has been Chairman of the Board of Management of Biotest AG since January 2015. Prior to this, he worked for the Imclone Group, a wholly owned subsidiary of Eli Lilly, as President of Imclone Systems Corporation in the United States and as managing director in Germany. In 2007/2008 he was CEO of Fresenius Biotech, Germany and before this, Dr. Ehmer headed the Business Area Oncology of Merck KGaA, Darmstadt and served as head of Global Clinical Operations at Merck. Between 1986 and 1998 he held various functions at Boehringer Mannheim in Germany, Italy and Singapore. Dr. Ehmer holds a degree in medicine and worked in the Department of Internal Medicine at the Academic Teaching Hospital of the University of Heidelberg.
 
 
 



 
  Impressum Disclaimer